OncoMatch/Clinical Trials/NCT06954805
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Is NCT06954805 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for lymphoma.
Treatment: Rituximab · Etoposide · Prednisone · Vincristine · Cyclophosphamide · Doxorubicin · CAPP-seq — The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd phase of treatment (consolidation) while those with low-risk disease will be spared of chemotherapy and treated with rituximab consolidation alone. This study is also being done to find out about the usefulness of circulating tumor DNA (ctDNA), a novel blood test which, has been shown to help guide treatment decisions in other types of lymphoma. The goal is to answer the question if ctDNA is a viable and informative tool in treating PTLD with the hope that in the future it may be used to individualize study treatment for participants with PTLD in a way that limits study treatment toxicity without losing the effectiveness of the treatment plan.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (positive)
Histologically confirmed CD20+ PTLD
Prior therapy
Cannot have received: systemic chemotherapy
Exception: for PTLD
Patients who have received systemic chemotherapy for PTLD.
Cannot have received: chemotherapy
Exception: for other indications within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study and must have recovered from adverse events due to agents administered more than 4 weeks earlier
Participants must not have had chemotherapy for other indications within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study and must have recovered from adverse events due to agents administered more than 4 weeks earlier.
Cannot have received: anthracycline (doxorubicin, epirubicin)
Exception: must not have received more than a cumulative dose 250 mg/m2 of prior doxorubicin (or equivalent dose of another anthracycline, such as epirubicin) therapy (at any time prior to registration)
Participants must not have received more than a cumulative of dose 250 mg/m2 of prior doxorubicin (or equivalent dose of another anthracycline, such as epirubicin) therapy (at any time prior to registration).
Lab requirements
Blood counts
Organ function as assessed by laboratory testing is in appropriate range for receipt of rituximab and R-EPOCH per individual treating physician discretion.
Kidney function
Organ function as assessed by laboratory testing is in appropriate range for receipt of rituximab and R-EPOCH per individual treating physician discretion.
Liver function
Organ function as assessed by laboratory testing is in appropriate range for receipt of rituximab and R-EPOCH per individual treating physician discretion.
Cardiac function
Cardiac function testing is in appropriate range for receipt of rituximab and R-EPOCH per individual treating physician discretion.
Organ function as assessed by laboratory testing is in appropriate range for receipt of rituximab and R-EPOCH per individual treating physician discretion. Cardiac function testing is in appropriate range for receipt of rituximab and R-EPOCH per individual treating physician discretion.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Medical Center · Stanford, California
- Columbia University Irving Medical Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify